Manufacturer:
Akrimax Pharmaceuticals
Pharmacological Class:
Sympathomimetic.
Active Ingredient(s):
Phentermine HCl 15mg, 30mg, 37.5mg; orally-disintegrating tabs (ODT); peppermint-flavor.
Indication(s):
A short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30kg/m2, or ≥27kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, hyperlipidemia).
Pharmacology:
Suprenza is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics’ or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects may also be involved.
Clinical Trials:
No clinical studies have been conducted with Suprenza.
Legal Classification:
CIV
Adults:
Individualize. Use lowest effective dose. Allow tablet to dissolve on tongue, then swallow. >16yrs: usually one tab daily in the AM. Avoid late PM dose.
Children:
≤16yrs: not recommended.
Contraindication(s):
Cardiovascular disease (eg, coronary artery disease, stroke, arrhythmias, CHF, uncontrolled hypertension). Hyperthyroidism. Glaucoma. Agitated states. History of drug abuse. During or within 14 days of MAOIs. Pregnancy (Cat.X). Nursing mothers.
Warnings/Precautions:
Increased risk of primary pulmonary hypertension (PPH), valvular heart disease. Discontinue if unexplained dyspnea, angina pectoris, syncope, or lower extremity edema develops. Discontinue if tolerance to anorectant effect occurs. Mild hypertension. Diabetes. Renal impairment. Prescribe minimal supply to avoid overdose. Elderly.
Interaction(s):
See Contraindications. Hypertensive crisis possible with MAOIs. Concomitant other weight loss drugs, including SSRIs (fluoxetine, sertraline, fluvoxamine, paroxetine): not recommended. Caution with alcohol. Insulin and oral hypoglycemics: requirements may be altered. May decrease hypotensive effect of adrenergic neuron blocking drugs.
Adverse Reaction(s):
Cardiovascular (eg, PPH, regurgitant cardiac valvular disease, palpitations, tachycardia, elevated blood pressure, ischemic events, CNS (eg, overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis), dry mouth, unpleasant taste, GI upset, constipation, urticaria, impotence, changes in libido.
How Supplied:
ODT—30, 100
Last Updated:
6/4/2012
制造商：
akrimax制药
类药物：
交感神经。
活性成分（S）：
盐酸芬特明15毫克，30毫克，37.5mg口服崩解的标签（ODT）的;薄荷味。
芬特明
Phentermine
中文别名： 芬特明、苯丁胺
英文别名： Duromine、Ionamine、Mirapont、Mirapront、Omnibex
不同适应症和各年龄组别患者的用法用量 口服给药
中重度肥胖症短期治疗中抑制食欲
成人:
离子交换树脂复合物（缓释剂）：15-30 mg，每天一次口服。盐酸芬特明：8 mg tid，或15-37.5 mg/天，早晨顿服。
药物过量:慢性中毒: 活动过度, 易激惹, 严重失眠, 人格异常, 精神异常, 严重皮肤病。急性过量: 攻击行为，心律失常，高/低血压, 循环虚脱, 意识混乱,中枢神经系统兴奋后抑制和疲乏, 胃肠道症状, 体温过高, 惊恐, 不安, 横纹肌溶解, 呼吸急促震颤, 瞳孔扩大, 惊厥,心动过速。处理：支持疗法。
禁忌
肺动脉高压, 晚期动脉粥样硬化, 中到重度高血压, 甲状腺机能亢进, 心血管系统疾病, 青光眼, 药物滥用史, 激越状态，及单胺氧化酶治疗期间或停药后14天内禁用。
不良反应:荨麻疹，胃肠道不适，心悸，心动过速，血压升高, 过度刺激, 不安, 失眠, 震颤, 头痛, 口干, 头晕, 烦躁, 欣快感, 精神异常, 性欲改变, 阳痿。
严重不良反应:
原发性肺动脉高压和心脏瓣膜疾病。
药物相互作用 抗酸剂和碳酸酐酶抑制剂(如乙酰唑胺、二氯磺胺和甲醋唑胺)会降低本药的排泄。与拟交感神经胺合用，发生副作用的风险增加。
严重药物相互作用:
抗酸剂和碳酸酐酶抑制剂(如乙酰唑胺、二氯磺胺和甲醋唑胺)会降低本药的排泄。与拟交感神经胺合用，发生副作用的风险增加。
查看 芬特明[phentermine]详细药物相互作用
与食物的相互作用 早餐前或早餐后1-2小时（盐酸芬特明）服用；睡前10-14小时（芬特明酯）服用。
FDA妊娠分级
C级:
动物研究证明药物对胎儿有危害性（致畸或胚胎死亡等），或尚无设对照的妊娠妇女研究，或尚未对妊娠妇女及动物进行研究。本类药物只有在权衡对孕妇的益处大于对胎儿的危害之后，方可使用。
药理作用 芬特明是一种间接作用的拟交感神经药，具有α-和β-肾上腺素能激动活性。芬特明能刺激大脑皮层，抑制食欲，用于减重治疗。
吸收: 口服后经胃肠道吸收容易，树脂化剂型吸收缓慢。
排泄: 部分以药物原形、部分以代谢产物的形式经尿液排泄。
